Abstract Number: 1014 • ACR Convergence 2023
Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Therapy and Subsequent Referrals to Rheumatologists at a Private vs Public Medical Center in Los Angeles: Ramifications for Health Disparities
Background/Purpose: Immune checkpoint inhibitors (ICIs) represent a breakthrough in cancer therapies. However, ICIs may be associated with significant immune-related adverse events (irAEs), including rheumatic irAEs.…Abstract Number: 1481 • ACR Convergence 2023
Racial Disparities in Lupus Nephritis: A Nationwide Analysis
Background/Purpose: Lupus nephritis (LN) is a significant predictor of morbidity and mortality in Systemic Lupus Erythematosus (SLE). Racial disparities are known to exist in SLE…Abstract Number: 2460 • ACR Convergence 2023
Health Care Segregation, but Not Metropolitan Area Segregation, Magnifies Racial Disparities in Hospital Outcomes of Pediatric Lupus
Background/Purpose: Racial disparities and hospital-level variation in pediatric SLE (pSLE) outcomes are well described, but it is not known how the racial and ethnic composition…Abstract Number: 0186 • ACR Convergence 2023
Retention in Rheumatology Care and on Hydroxychloroquine and SLE Outcomes by Neighborhood Disadvantage: A Medicare Cohort Study of Acute Care and Kidney Failure
Background/Purpose: Gaps in systemic lupus (SLE) care are believed to contribute to higher kidney failure (ESKD), acute care use, mortality, and disease damage in US…Abstract Number: 1015 • ACR Convergence 2023
Health Care Access in an Indigenous North American Population of Rheumatoid Arthritis Patients and Their At-risk First-Degree Relatives
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic autoimmune disease that requires access to subspecialty care. Although Canada has a universal healthcare system, there are complex…Abstract Number: 1615 • ACR Convergence 2023
Therapeutic Hydroxychloroquine Blood Levels Are Cost Effective and May Reduce Health Disparities by Reducing Lupus Hospitalizations
Background/Purpose: Studies show factors including daily hydroxychloroquine (HCQ) dosing or nonadherence affect blood concentrations risking 6-fold higher lupus (or SLE) flares requiring hospitalization. Given disparities…Abstract Number: 0187 • ACR Convergence 2023
Advancing Health Equity with Lupus Stakeholders to Close Care Gaps and Disparities
Background/Purpose: Systemic lupus erythematosus (SLE) care and outcomes are associated with significant racial and socioeconomic disparities in the US, particularly among young Black and Hispanic/Latina…Abstract Number: 1018 • ACR Convergence 2023
Recognizing Rural Healthcare Disparities in Pain Assessment for Autoimmune Rheumatologic Diseases
Background/Purpose: Pain is a common complaint seen in many autoimmune rheumatologic conditions, along with decreased function and decreased sense of well-being. Pain is a highly…Abstract Number: 1616 • ACR Convergence 2023
Geographic and Demographic Representation in Industry-sponsored, US-based Clinical Trials of Systemic Lupus Erythematosus Therapies
Background/Purpose: Clinical trials of systemic lupus erythematosus (SLE) therapies have increased over the last decade, driven by evolving knowledge of targetable pathways. However, these trials…Abstract Number: 0189 • ACR Convergence 2023
Influence of Social Support on Systemic Lupus Erythematosus (SLE) Outcomes in a Health Disparity Population
Background/Purpose: SLE disproportionately impacts African American women. Social support may have a positive impact in SLE and as such could potentially reduce disease burden. However,…Abstract Number: 1019 • ACR Convergence 2023
Association of Historical Redlining and Present-Day Neighborhood Inequities with Missed Outpatient Appointments Among Individuals with Rheumatic Conditions
Background/Purpose: Structural racism pervades U.S. history with continued effects on health inequities. Residential segregation serves as an example, where redlining maps outlined areas with high…Abstract Number: 1624 • ACR Convergence 2023
Racial Disparities Impact Achieving LLDAS and Glucocorticoid Use in Pediatric Lupus: A CARRA Registry Study
Background/Purpose: Social determinants of health (SDoH) contribute to disparate outcomes in both adult and pediatric systemic lupus erythematosus (pSLE), including length of hospitalization, mortality, and…Abstract Number: 014 • 2023 Pediatric Rheumatology Symposium
Characterizing Lupus in African American Children in Southern United States
Background/Purpose: African-American (AA) ethnicity is a known predisposing factor for childhood onset systemic lupus erythematosus (cSLE) and a predictor of poor outcomes. In addition to…Abstract Number: 025 • 2023 Pediatric Rheumatology Symposium
Patient- and Center-level Risk Factors for Research Lost to Follow-up Using the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Background/Purpose: Clinical registries are typically envisioned to be representative of a target patient population and reflective of health care delivery practices for said population. Variation…Abstract Number: 085 • 2023 Pediatric Rheumatology Symposium
Identification of Barriers to Care Experienced by Children with Rheumatic Disease: A Qualitative Study
Background/Purpose: Pediatric rheumatic diseases are known to have disparities in disease outcomes, but many drivers of these inequities are unknown. Social determinants of health are…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 18
- Next Page »